Guideline for the treatment of chronic lymphocytic leukaemia

Renata Walewska¹, Nilima Parry-Jones², Toby A Eyre³, George Follows⁴, Nicolas Martinez-Calle⁵, Helen McCarthy¹, Helen Parry^{6

7}, Piers E M Patten^{8

9}, John C Riches¹⁰, Peter Hillmen^{11

12}, Anna H Schuh^{3

13}

Affiliations

¹ Department of Haematology, University Hospitals Dorset, Bournemouth, UK.
² Department of Haematology, Aneurin Bevan University Health Board, Wales, UK.
³ Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁴ Department of Haematology, Addenbrookes, Cambridge, UK.
⁵ Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁶ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
⁷ University Hospitals Birmingham NHS Trust, Birmingham, UK.
⁸ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
⁹ Department of Haematology, King's College Hospital NHS Trust, London, UK.
¹⁰ Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
¹¹ St. James's Institute of Oncology, Leeds, UK.
¹² Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
¹³ Department of Oncology, University of Oxford, John Radcliffe Hospital, Oxford, UK.

Renata Walewska et al. Br J Haematol. 2022 Jun.

. 2022 Jun;197(5):544-557.

doi: 10.1111/bjh.18075. Epub 2022 Mar 21.

¹ Department of Haematology, University Hospitals Dorset, Bournemouth, UK.
² Department of Haematology, Aneurin Bevan University Health Board, Wales, UK.
³ Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁴ Department of Haematology, Addenbrookes, Cambridge, UK.
⁵ Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁶ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
⁷ University Hospitals Birmingham NHS Trust, Birmingham, UK.
⁸ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
⁹ Department of Haematology, King's College Hospital NHS Trust, London, UK.
¹⁰ Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
¹¹ St. James's Institute of Oncology, Leeds, UK.
¹² Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
¹³ Department of Oncology, University of Oxford, John Radcliffe Hospital, Oxford, UK.

No abstract available

Keywords: CLL; Covid19; treatment; vaccination.

References

1. Schuh AH, Parry-Jones N, Appleby N, Bloor A, Dearden CE, Fegan C, et al. Guideline for the treatment of chronic lymphocytic leukaemia: a British Society for Haematology Guideline. Br J Haematol. 2018;182(3):344-59.
1. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, et al. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol. 2022;196(1):70-8.
1. Eyre TA, Riches JC, Patten PEM, Walewska R, Marr H, Follows G, et al. Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. Br J Haematol. 2022;196(4):864-70.
1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
1. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49-56.